Keep up to date with who we are, where we will be and how we are embracing the future here.
Cello Health are pleased to announce our presence BIO 2018 on June 4–7 in Boston. Stop by booth #2122 to speak to one of our team about our capabilities and experience in supporting BioPharm clients from asset identification or acquisition through to informing the Phase 3 programme. We will have representatives from all areas of […]More +
Cello Health Insight is very pleased to announce that it has been named ranked #4 among the top 27 small employers in the state, according to the New York State Society for Human Resource Management’s (NYS-SHRM) annual Best Companies to Work for in New York State awards program. Kathryn Gallant, CEO, Cello Health Insight, US […]More +
The new European General Data Protection Regulation (GDPR) law will come into effect on 25 May 2018. The aim of this law is to ensure all personal data relating to living EU citizens (including the UK) is protected and the companies who work with such data are held accountable for its protection. We at Cello […]More +
Regardless of how innovative a new technology may be, all therapeutic approaches face increasing pressure on target product profiles. Determining what benchmarks novel therapies will need to demonstrate in order to prove differentiation and therapeutic value and compete in the changing rare disease landscape should be an early priority for developers. The transformation of the […]More +
Come and meet Cello Health at the World Orphan Drugs Congress, April 25–27, at the Gaylord National Harbor Hotel, Oxon Hill, MD, USA. We are pleased to have representatives from Communications, Consulting and Insight attending the congress. Stop by booth 812 to speak to one of our team about our capabilities and extensive experience in rare diseases and orphan drugs. To […]More +